ALK and non-small cell lung carcinoma: Our study demonstrated that 2 low-fusion frequency cases (NGS ALK gene fusion analysis) benefited from crizotinib therapy, suggesting that NSCLC patients with a low frequency of ALK fusion genes may also benefit from ALK-TKI treatment.